Theravance Inc. (THRX): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Theravance ( THRX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 2.5%. By the end of trading, Theravance fell $0.65 (-1.8%) to $36.23 on heavy volume. Throughout the day, 1,507,635 shares of Theravance exchanged hands as compared to its average daily volume of 948,200 shares. The stock ranged in price between $36.02-$37.39 after having opened the day at $37.26 as compared to the previous trading day's close of $36.88. Other companies within the Drugs industry that declined today were: Bioline Rx ( BLRX), down 13.0%, Atossa Genetics ( ATOS), down 11.3%, OvaScience ( OVAS), down 9.5% and Aoxing Pharmaceutical Company ( AXN), down 7.8%.

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. Theravance has a market cap of $4.1 billion and is part of the health care sector. Shares are up 3.5% year to date as of the close of trading on Monday. Currently there are 5 analysts that rate Theravance a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Theravance as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share.

On the positive front, Rosetta Genomics ( ROSG), up 26.5%, Egalet ( EGLT), up 16.0%, Corcept Therapeutics ( CORT), up 15.7% and China Pharma ( CPHI), up 14.9% , were all gainers within the drugs industry with Pfizer ( PFE) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Theravance (THRX) Highlighted As Weak On High Volume

Theravance (THRX) Highlighted As Weak On High Volume

Theravance (THRX) Flagged As Strong On High Volume

Theravance (THRX) Flagged As Strong On High Volume

3 Sell-Rated Dividend Stocks: VER, BRS, THRX

3 Sell-Rated Dividend Stocks: VER, BRS, THRX

The 10 Highest Dividend Health Care Stocks Are Not All Buys

The 10 Highest Dividend Health Care Stocks Are Not All Buys

5 Hated Stocks You Should Love This Earnings Season

5 Hated Stocks You Should Love This Earnings Season